Why carry out this study?

Migraine is a chronic neurologic disease characterized by recurrent attacks that involve headache, as well as neurologic and autonomic symptoms that can be disabling.

Acute treatments are often used to reduce migraine-related symptoms and disability associated with attacks; however, a subset of individuals may also require preventive treatment to reduce the frequency of attacks and these individuals represent a more severely affected subgroup due to greater attack frequency, severity, or both.

The objective of this analysis was to evaluate the impact of preventive medication use on the efficacy and safety of ubrogepant for the acute treatment of migraine.

What was learned from the study?

Ubrogepant was associated with significant efficacy across all three outcome measures (pain freedom, absence of most bothersome symptom, and pain relief at 2 h after ubrogepant administration) in people with migraine regardless of preventive medication use, and responder rates were not significantly different between participants with or without preventive medication use.

The results of this study indicate that ubrogepant is safe to use with the preventive medications assessed in this analysis, and can be applied to clinical practice, especially when considering the potential for drug–drug interactions.